Stock AnalizMedpace (MEDP) earnings for the quarter ended September 2026: EPS beats estimates
Medpace reported results for the quarter ended September 2026 on October 21, 2026. Adjusted earnings per share came in at $4.84 against the analysts’ average forecast of $4.46, a beat of 8.5%.
Revenue for the quarter was $716 million, up 8.5% from $660 million in the same quarter a year earlier.
The market’s verdict: the stock rose 5.1% on the first trading day after the report.
The last four quarters
Medpace has beaten the analysts’ EPS forecast in 4 of the last 4 quarters.
| Quarter | EPS | Forecast | Surprise | Revenue growth | Price reaction |
|---|---|---|---|---|---|
| Sep 2026 | $4.84 | $4.46 | +8.5% | +9% | +5.1% |
| Jun 2026 | $4.25 | $4.00 | +6.2% | +17% | +14.0% |
| Mar 2026 | $4.28 | $3.96 | +8.2% | +27% | −23.6% |
| Dec 2025 | $4.67 | $4.23 | +10.5% | +32% | −17.7% |
What comes next
Analysts expect EPS of $4.88 for the next quarter on average and $18.36 for the fiscal year ending December 31, 2026.
The average analyst price target is $651.31, 0% below the current price of $653.94.
Valuation and score
Medpace scores 3.2 out of 5 overall on Stock Analiz (good, with some weak spots), trades at a trailing P/E of about 36.3, and its intrinsic value under moderate assumptions is about 32% below the current market value. Full Medpace analysis with 10 years of financials
Frequently asked questions
What was Medpace’s EPS for the quarter ended September 2026?
$4.84 adjusted per share, against an analyst consensus of $4.46.
How much revenue did Medpace report?
$716 million, up 8.5% year over year.
More
This report was written automatically from the published numbers within hours of the release. It is information, not investment advice.